Biosimilar biological drugs in the treatment of inflammatory bowel diseases
Within the last 20 years, tumour necrosis factor inhibitors have been proven to be effective in achieving and maintaining clinical and endoscopic remission in patients with Crohn’s disease and ulcerative colitis. Since 2013, when infliximab originator lost its patent protection, patients with inflam...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2019-12-01
|
| Series: | Gastroenterology Review |
| Subjects: | |
| Online Access: | https://www.termedia.pl/Biosimilar-biological-drugs-in-the-treatment-of-inflammatory-bowel-diseases,41,38709,1,1.html |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841548449323941888 |
|---|---|
| author | Magdalena Kaniewska Piotr Eder Anita Gąsiorowska Maciej Gonciarz Jarosław Kierkuś Ewa Małecka-Panas Grażyna Rydzewska |
| author_facet | Magdalena Kaniewska Piotr Eder Anita Gąsiorowska Maciej Gonciarz Jarosław Kierkuś Ewa Małecka-Panas Grażyna Rydzewska |
| author_sort | Magdalena Kaniewska |
| collection | DOAJ |
| description | Within the last 20 years, tumour necrosis factor inhibitors have been proven to be effective in achieving and maintaining clinical and endoscopic remission in patients with Crohn’s disease and ulcerative colitis. Since 2013, when infliximab originator lost its patent protection, patients with inflammatory bowel diseases (IBDs) in Poland have also been treated with biosimilar drugs. Biosimilars are drugs with high similarity to their reference products in terms of physicochemical properties, including structure, safety, and efficacy. Biosimilars are approved for use on the basis of the same rigorous quality standards as their reference products. In 2018, also biosimilars of adalimumab have become available. Studies published to date have shown that biosimilars do not differ from reference drugs in terms of the efficacy and safety. There are numerous data to confirm that a single switch of biological drugs (mainly from reference to biosimilar drugs) has no effect on therapy efficacy and safety. However, a significantly lower cost of therapy with biosimilars not only allows us to treat a much larger number of patients but may also necessitate multiple switches from reference drugs to biosimilars (including biosimilars produced by different manufacturers). Recently, the first results have been published concerning multiple switches in patients with psoriasis and rheumatoid arthritis. However, no such data are currently available for patients with IBDs. |
| format | Article |
| id | doaj-art-f110cf30d4614d73a4d459105355d4ed |
| institution | Kabale University |
| issn | 1895-5770 1897-4317 |
| language | English |
| publishDate | 2019-12-01 |
| publisher | Termedia Publishing House |
| record_format | Article |
| series | Gastroenterology Review |
| spelling | doaj-art-f110cf30d4614d73a4d459105355d4ed2025-01-10T14:06:14ZengTermedia Publishing HouseGastroenterology Review1895-57701897-43172019-12-0114422322710.5114/pg.2019.9009338709Biosimilar biological drugs in the treatment of inflammatory bowel diseasesMagdalena KaniewskaPiotr EderAnita GąsiorowskaMaciej GonciarzJarosław KierkuśEwa Małecka-PanasGrażyna RydzewskaWithin the last 20 years, tumour necrosis factor inhibitors have been proven to be effective in achieving and maintaining clinical and endoscopic remission in patients with Crohn’s disease and ulcerative colitis. Since 2013, when infliximab originator lost its patent protection, patients with inflammatory bowel diseases (IBDs) in Poland have also been treated with biosimilar drugs. Biosimilars are drugs with high similarity to their reference products in terms of physicochemical properties, including structure, safety, and efficacy. Biosimilars are approved for use on the basis of the same rigorous quality standards as their reference products. In 2018, also biosimilars of adalimumab have become available. Studies published to date have shown that biosimilars do not differ from reference drugs in terms of the efficacy and safety. There are numerous data to confirm that a single switch of biological drugs (mainly from reference to biosimilar drugs) has no effect on therapy efficacy and safety. However, a significantly lower cost of therapy with biosimilars not only allows us to treat a much larger number of patients but may also necessitate multiple switches from reference drugs to biosimilars (including biosimilars produced by different manufacturers). Recently, the first results have been published concerning multiple switches in patients with psoriasis and rheumatoid arthritis. However, no such data are currently available for patients with IBDs.https://www.termedia.pl/Biosimilar-biological-drugs-in-the-treatment-of-inflammatory-bowel-diseases,41,38709,1,1.htmlbiosimilar drugs crohn’s disease reference biologics inflammatory bowel disease ulcerative colitis |
| spellingShingle | Magdalena Kaniewska Piotr Eder Anita Gąsiorowska Maciej Gonciarz Jarosław Kierkuś Ewa Małecka-Panas Grażyna Rydzewska Biosimilar biological drugs in the treatment of inflammatory bowel diseases Gastroenterology Review biosimilar drugs crohn’s disease reference biologics inflammatory bowel disease ulcerative colitis |
| title | Biosimilar biological drugs in the treatment of inflammatory bowel diseases |
| title_full | Biosimilar biological drugs in the treatment of inflammatory bowel diseases |
| title_fullStr | Biosimilar biological drugs in the treatment of inflammatory bowel diseases |
| title_full_unstemmed | Biosimilar biological drugs in the treatment of inflammatory bowel diseases |
| title_short | Biosimilar biological drugs in the treatment of inflammatory bowel diseases |
| title_sort | biosimilar biological drugs in the treatment of inflammatory bowel diseases |
| topic | biosimilar drugs crohn’s disease reference biologics inflammatory bowel disease ulcerative colitis |
| url | https://www.termedia.pl/Biosimilar-biological-drugs-in-the-treatment-of-inflammatory-bowel-diseases,41,38709,1,1.html |
| work_keys_str_mv | AT magdalenakaniewska biosimilarbiologicaldrugsinthetreatmentofinflammatoryboweldiseases AT piotreder biosimilarbiologicaldrugsinthetreatmentofinflammatoryboweldiseases AT anitagasiorowska biosimilarbiologicaldrugsinthetreatmentofinflammatoryboweldiseases AT maciejgonciarz biosimilarbiologicaldrugsinthetreatmentofinflammatoryboweldiseases AT jarosławkierkus biosimilarbiologicaldrugsinthetreatmentofinflammatoryboweldiseases AT ewamałeckapanas biosimilarbiologicaldrugsinthetreatmentofinflammatoryboweldiseases AT grazynarydzewska biosimilarbiologicaldrugsinthetreatmentofinflammatoryboweldiseases |